Latest Insider Transactions at Celularity Inc (CELU)
This section provides a real-time view of insider transactions for Celularity Inc (CELU). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Celularity Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Celularity Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 13
2024
|
Stephen Brigido Pres, Functional Regeneration |
SELL
Payment of exercise price or tax liability
|
Direct |
268
-1.36%
|
$1,072
$4.11 P/Share
|
|
Apr 13
2024
|
Robert J Hariri Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,154
-0.04%
|
$4,616
$4.11 P/Share
|
|
Apr 13
2024
|
David C Beers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
360
-1.48%
|
$1,440
$4.11 P/Share
|
|
Apr 13
2024
|
John R Haines Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
576
-1.48%
|
$2,304
$4.11 P/Share
|
|
Apr 13
2024
|
Kyle Fletcher Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20
-0.09%
|
$80
$4.11 P/Share
|
|
Mar 15
2024
|
Kyle Fletcher Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
617
-2.84%
|
$3,085
$5.68 P/Share
|
|
Feb 17
2024
|
Adrian Kilcoyne Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
52,762
-4.49%
|
$0
$0.43 P/Share
|
|
Feb 17
2024
|
John R Haines Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
70,350
-15.3%
|
$0
$0.43 P/Share
|
|
Feb 17
2024
|
David C Beers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43,968
-15.3%
|
$0
$0.43 P/Share
|
|
Feb 17
2024
|
Kyle Fletcher Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
39,571
-15.41%
|
$0
$0.43 P/Share
|
|
Feb 17
2024
|
Stephen Brigido Pres, Functional Regeneration |
SELL
Payment of exercise price or tax liability
|
Direct |
32,720
-14.22%
|
$0
$0.43 P/Share
|
|
Jan 12
2024
|
Kok Thay Lim |
BUY
Open market or private purchase
|
Indirect |
21,410,983
+29.38%
|
$0
$0.25 P/Share
|
|
Oct 05
2023
|
Robert J Hariri Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,357,585
+14.73%
|
$0
$0.16 P/Share
|
|
Oct 05
2023
|
Sorrento Therapeutics, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,307,158
-55.53%
|
-
|
|
Sep 29
2023
|
Robert J Hariri Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,064,539
+32.06%
|
$0
$0.17 P/Share
|
|
Sep 29
2023
|
Sorrento Therapeutics, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
9,064,539
-44.39%
|
-
|
|
Jul 14
2023
|
Adrian Kilcoyne Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
875,000
+42.68%
|
-
|
|
Jun 14
2023
|
Diane L. Parks Director |
BUY
Grant, award, or other acquisition
|
Direct |
199,921
+45.85%
|
-
|
|
Jun 14
2023
|
John Sculley Director |
BUY
Grant, award, or other acquisition
|
Direct |
199,921
+16.6%
|
-
|
|
Jun 14
2023
|
Andrew C. Von Eschenbach Director |
BUY
Grant, award, or other acquisition
|
Direct |
199,921
+37.3%
|
-
|
|
Jun 14
2023
|
Marc Mazur Director |
BUY
Grant, award, or other acquisition
|
Direct |
199,921
+45.85%
|
-
|
|
Jun 14
2023
|
Robin L Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
199,921
+45.85%
|
-
|
|
Jun 14
2023
|
Dean C Kehler Director |
BUY
Grant, award, or other acquisition
|
Direct |
199,921
+45.85%
|
-
|
|
Jun 14
2023
|
Kok Thay Lim |
BUY
Grant, award, or other acquisition
|
Direct |
199,921
+45.85%
|
-
|
|
Jun 14
2023
|
Peter Diamandis Director |
BUY
Grant, award, or other acquisition
|
Direct |
199,921
+13.27%
|
-
|
|
Apr 13
2023
|
Robert J Hariri Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,540
-0.11%
|
$0
$0.71 P/Share
|
|
Apr 13
2023
|
Kyle Fletcher Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
201
-0.08%
|
$0
$0.71 P/Share
|
|
Apr 13
2023
|
Stephen Brigido Pres, Functional Regeneration |
SELL
Payment of exercise price or tax liability
|
Direct |
2,683
-1.15%
|
$0
$0.71 P/Share
|
|
Apr 13
2023
|
John R Haines Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,770
-1.24%
|
$0
$0.71 P/Share
|
|
Apr 13
2023
|
David C Beers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,606
-1.24%
|
$0
$0.71 P/Share
|
|
Apr 13
2023
|
Bradley Glover Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,884
-0.81%
|
$0
$0.71 P/Share
|
|
Mar 27
2023
|
Robert J Hariri Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,084,854
+17.03%
|
$0
$0.83 P/Share
|
|
Mar 15
2023
|
Kyle Fletcher Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,170
-0.84%
|
$0
$0.63 P/Share
|
|
Feb 17
2023
|
John R Haines Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+46.21%
|
-
|
|
Feb 17
2023
|
Kyle Fletcher Officer |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+46.47%
|
-
|
|
Feb 17
2023
|
Stephen Brigido Pres, Functional Regeneration |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+46.21%
|
-
|
|
Feb 17
2023
|
Bradley Glover Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+45.87%
|
-
|
|
Feb 17
2023
|
David C Beers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+46.21%
|
-
|
|
Feb 17
2023
|
Adrian Kilcoyne Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+50.0%
|
-
|
|
Feb 10
2023
|
Peter Diamandis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,071,000
+49.17%
|
$0
$0.28 P/Share
|
|
Nov 30
2022
|
Robert J Hariri Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+0.12%
|
$10,000
$1.72 P/Share
|
|
Nov 29
2022
|
Robert J Hariri Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
40,000
+0.49%
|
$40,000
$1.71 P/Share
|
|
Nov 28
2022
|
Robert J Hariri Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
40,000
+0.5%
|
$40,000
$1.74 P/Share
|
|
Nov 16
2022
|
Kyle Fletcher Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,262
-3.56%
|
$1,262
$1.89 P/Share
|
|
Nov 16
2022
|
Anne Jones Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,734
-7.06%
|
$3,734
$1.89 P/Share
|
|
Aug 26
2022
|
John Sculley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
768,594
+48.85%
|
$0
$0.28 P/Share
|
|
Aug 24
2022
|
Robert J Hariri Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
119,073
+1.47%
|
$238,146
$2.87 P/Share
|
|
Jul 13
2022
|
Peter Diamandis Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,145
+50.0%
|
-
|
|
Jul 13
2022
|
John Sculley Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,145
+50.0%
|
-
|
|
Jul 13
2022
|
Kok Thay Lim |
BUY
Grant, award, or other acquisition
|
Direct |
36,145
+50.0%
|
-
|